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Responding to new psychoactive substances
As criminal laws should clearly deﬁ ne 
those substances under control, the 
discovery of a psychoactive substance 
outside legal control can allow suppliers 
to make a proﬁ t at unknown risk to the 
health of the consumers. These substances 
may then be identiﬁ ed by the authorities 
and added to the list of those controlled, 
and so the cycle begins again. Recent 
developments allowing organic chemicals 
to be synthesised cheaply, combined with 
the information exchange and marketing 
possibilities aﬀ orded by the Internet, have 
led to new psychoactive substances 
becoming widely available at an 
unprecedented pace. These may be 
marketed through shops specialising in 
drug paraphernalia in town centres and 
easily established websites, which have 
the potential to spread the use of a new 
drug rapidly within countries and 
internationally. The speed at which new 
psychoactive substances can appear and 
be distributed now challenges the 
established procedure of passing 
legislation to control a substance in each 
country. Suppliers are making substantial 
proﬁ ts during the months required to 
control a new substance under criminal 
law and while the risks associated with its 
use have yet to be determined. 
Policymakers are demanding new, faster 
and eﬀ ective ways of drug control that 
will protect public health and, if possible, 
deter the suppliers from ﬁ nding a new 
substance to continue the cycle.
Key issues at a glance
1. New psychoactive substances are not easily 
detected and identiﬁ ed by forensic laboratories. 
Testing products for unknown or unexpected 
substances is time consuming, complex and 
expensive. This may hinder targeted and timely 
responses by legislators and law enforcement.
4. The legislative procedure required to bring a 
substance under the control of the drug laws takes 
time, in some countries more than a year.
2. It is not legally possible to criminalise the 
unauthorised distribution of all psychoactive 
substances, so legislation, rather than being 
proactive, can only react to substances as they 
appear.
5. Controlling a new psychoactive substance might have 
unintended and unwanted consequences. It may 
stimulate the search for, and distribution of, a non-
controlled replacement, possibly one more harmful 
than its predecessor. 
3. New psychoactive substances may pose risks to 
individual and public health as well as social risks, 
aﬀ ecting the broader community. However, when 
they ﬁ rst appear on the market, information on 
their associated risks is lacking.
6. Other control options, though faster, lack the penalties 
to send the same messages of deterrence and health 
risk. Furthermore, they might not be eﬀ ective in 
preventing or stopping the marketing and distribution 
of a new substance.
Deﬁ nition 
New psychoactive substance: A new narcotic or psychotropic drug, in pure form or in preparation, that is not 
controlled by the 1961 United Nations Single Convention on Narcotic Drugs or the 1971 United Nations Convention 
on Psychotropic Substances, but which may pose a public health threat comparable to that posed by substances listed 
in these conventions (Council Decision 2005/387/JHA).
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Member States require the capacity 
to rapidly identify and scientiﬁ cally 
evaluate the increasingly diverse and 
complex new substances appearing on 
the market. Their response mechanisms 
should be optimised to act eﬀ ectively 
and eﬃ  ciently to protect public health 
with the minimum adverse consequences; 
control under drug law is one of various 
options that can achieve this.
Wolfgang Götz, 
EMCDDA Director
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1. Early-warning systems
In Europe, early-warning systems for new 
psychoactive substances work at both EU 
and national levels. The European 
early-warning system, which was 
established in 1997, is implemented by 
the EMCDDA and Europol and builds on 
the national systems. It is a 
multidisciplinary network, which collects, 
appraises and rapidly disseminates 
information on new drugs and products 
containing them. The last two years have 
seen a record number of new substances 
identiﬁ ed for the ﬁ rst time in Europe — 
24 in 2009 and 41 in 2010 (see graphic). 
Currently, about 150 substances are 
monitored at EU level. 
National early-warning systems have 
distinct structures or components 
depending on the speciﬁ c national needs 
and priorities, although also serving the 
needs of the European system. Across 
Europe, national early-warning systems 
diﬀ er in many ways, including their legal 
basis, their location in the government (in 
health or law enforcement bodies), their 
coverage (local, regional or national) and 
the resources allocated to them. They 
may also diﬀ er in their composition and 
capacity. For example, some early-
warning systems include strong forensic 
science and toxicology networks, some 
monitor samples collected from users and 
some are linked to a rapid response 
mechanism. National early-warning 
systems can be strengthened by the use 
of quantitative drug monitoring indicators, 
qualitative research and multidisciplinary 
information sources such as healthcare 
providers, law enforcement organisations 
and independent researchers. They may 
exploit the latest analytical and 
technological advances, and can beneﬁ t 
from eﬃ  cient and timely information 
exchange between all partners.
2. Proactive control
Psychoactive substances controlled under 
criminal law must be clearly deﬁ ned. The 
principle underlying this, enshrined in the 
European Convention on Human Rights 
and in some national constitutions, is that 
no one can be found guilty of an oﬀ ence 
that was not criminal at the time. From 
this, the European Court of Human Rights 
ruled that criminal law has to be speciﬁ c 
in what it classiﬁ es as an oﬀ ence. This 
would mean that substances not listed in 
the drug law are not controlled by it. 
European Court of Human Rights case-
law, however, allows certain elements of 
the oﬀ ence to be clariﬁ ed and brought 
under the original deﬁ nition of the 
oﬀ ence. Generic deﬁ nitions of chemical 
families of substances under control are 
used by Ireland and the United Kingdom. 
Analogues or derivatives of controlled 
drugs may mean those with similar 
structures or eﬀ ects and therefore cover a 
wider range of substances than a generic 
deﬁ nition. These can be applied to all 
substances under control in the drug law 
(as in Bulgaria, Norway), selected 
categories (Latvia, Malta) or just one 
small group (Luxembourg). Some Member 
States, however, reported that they would 
have diﬃ  culties implementing a generic 
deﬁ nition, as it would require changes to 
primary legislation or might contradict 
constitutional principles. In 2010, Ireland 
introduced legislation that prohibits the 
sale of any addictive or harmful 
psychoactive substances for human 
consumption and Poland prohibited the 
marketing of substitute drugs. It is too 
early to fully evaluate this approach. 
3. Assessing the risks
National systems to assess the risks 
presented by new psychoactive 
substances exist in most EU Member 
States. These systems examine the health 
and social risks posed by new substances 
at the various stages from manufacture, 
through traﬃ  cking to use. They may also 
evaluate the potential involvement of 
organised crime and the consequences of 
possible control measures. Out of 
26 countries for which information is 
available, six did not report having a risk 
assessment system as part of the legal 
procedure of control. A risk assessment 
system is directly referred to in the drug 
law of six countries, is semi-formalised in 
seven and can be performed on an ad 
hoc basis in another seven. It is carried 
out by public oﬃ  cials in the majority of 
countries, but by an independent scientiﬁ c 
body in four (Hungary, Netherlands, 
Austria, United Kingdom). 
About half of the EU Member States 
legally distinguish substances by the level 
of harm they may cause, and a risk 
assessment may assist with accurate 
classiﬁ cation and communication of the 
harms to the public. Media reporting of 
purported harms may increase pressure 
for legislative control before key facts are 
known. But, with indications that relatively 
few people use new psychoactive 
substances, care is needed not to lose 
credibility by overstating their risks. Few 
countries appear to reassess the accuracy 
of their classiﬁ cation when new 
information should be available.
4. Faster processes — 
but supervised
The amount of time it takes to put a new 
substance under control depends on the 
procedure followed, the nature of the 
law involved and the level of approval 
required. For example, a complex 
procedure to change a parliamentary 
law that requires the approval of the 
head of state will take longer than a 
simple procedure to change a regulation 
signed by one minister. To overcome 
procedural delays, Germany and the 
Netherlands have established 
emergency systems that enable a 
substance to be placed under temporary 
control for a year, with the approval of 
one minister rather than the government. 
If the procedure for permanent control is 
not followed within that year, the 
restriction will lapse. Several other 
countries have fast-track systems to place 
substances under permanent control by 
shortening deﬁ ned consultation periods 
during the law-making process. In 
Sweden, a separate law, the ‘Act on 
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goods dangerous to health’, allows the 
rapid classiﬁ cation of a substance as 
subject to serious criminal penalties for 
sale or possession, while the authorities 
consider if it meets the deﬁ nition of a 
‘drug’; in which case, it should eventually 
be listed as a controlled drug. Directive 
98/34/EC of the European Parliament 
and of the Council requires a three-
month notice period for national actions 
that limit intra-community trade, but this 
can be waived for serious public health 
or safety reasons.
5. Unintended consequences 
of control
The EU risk assessment procedure 
considers the possible consequences of 
control measures, which may include 
substitution of the newly controlled 
substance with another non-controlled 
substance — sometimes one which has 
more serious eﬀ ects. For example, control 
of GHB (gamma-hydroxybutyric acid) 
may have led to a rise in the use of its 
chemical and metabolic precursor 
GBL (gamma-butyrolactone), which is at 
least as dangerous as GHB. After 
hallucinogenic mushrooms containing 
psilocin were controlled, some retailers 
began to oﬀ er the mushroom Amanita 
muscaria, which has substantial toxicity 
risks. When mephedrone was placed under 
control in Europe, online retailers started to 
advertise naphyrone as a replacement. 
However, instead of naphyrone, many 
samples contained one or more controlled 
cathinones, or other substances chemically 
unrelated to naphyrone. 
Maintaining an elevated vigilance for 
new drugs can be expensive as it 
requires the identiﬁ cation of a growing 
number of new substances and research 
into their associated risks and responses. 
Bringing new psychoactive substances 
under drug law control also requires 
resources for enforcement. Countries 
applying this approach in all cases might 
run the risk of overloading their national 
system. With this in mind, scientiﬁ c risk 
assessment panels in the Netherlands 
and the United Kingdom have 
recommended against criminal control of 
the supply of certain substances 
(hallucinogenic mushrooms and khat 
respectively), favouring instead prevention 
programmes.
6. Are other laws effective?
Some European countries have 
successfully used other laws to stop the 
open distribution of a new drug. These 
laws are based on harmonised EU 
deﬁ nitions, which should be already 
operational in all Member States. For 
instance, regulations requiring that goods 
or food on sale are clearly and accurately 
labelled in relation to their expected use 
have been invoked to conﬁ scate Spice 
products not labelled in the national 
language (Italy), or mephedrone labelled 
as bath salts and plant food (United 
Kingdom). By applying the harmonised 
EU deﬁ nition of a medicinal product to a 
new psychoactive substance, national 
medicines agencies can prohibit its 
unauthorised importation, marketing or 
distribution. In 2009, Austria classiﬁ ed 
Spice products under non-criminal 
medicines legislation, and this proved 
eﬀ ective in stopping the open marketing 
and distribution of Spice in Austria, while 
avoiding criminalising users. Import bans 
in Austria (Spice) and in the United 
Kingdom (mephedrone) contributed to 
stopping open distribution.
Young people’s access to new 
substances can be reduced by licensing 
or age restrictions on sales outlets. These 
may be similar to those regulating 
alcohol and tobacco sales, but other 
examples include the ‘coﬀ ee shops’ in 
the Netherlands and the sale of butane 
and solvent products in the United 
Kingdom. 
All these approaches follow the recent 
recommendations of the United Nations 
Oﬃ  ce on Drugs and Crime to place an 
emphasis on enforcing laws to protect 
health and concentrate on suppliers 
rather than criminalising all users. 
Number of new psychoactive substances notiﬁ ed to the European 
early-warning system under Council Decision 2005/387/JHA
NB: Council Decision 2005/387/JHA came into eﬀ ect on 21 May 2005.
Source: European early-warning system.
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Conclusions and policy considerations
1. Detecting and identifying new psychoactive substances as they 
appear on the market are the ﬁ rst steps to assessing the risks of, 
and ultimately controlling, potentially dangerous new drugs. 
The capacity to achieve this task is an essential element of 
early-warning systems.
4. Drug laws should address substances that pose serious health 
and social threats. Other measures, combined with prevention 
programmes, may also be used to dissuade the use of 
non-controlled substances that are not necessarily safe.  
2. Risk assessment systems can provide evidence to support the 
legislative process. The results can send an accurate and 
credible message to the public about the risk of harm 
associated with the substance. Targeted research is key to 
providing a ﬁ rm evidence base for risk assessment and for 
ongoing justiﬁ cation of control measures.
5. It is important to consider if other laws already available, such 
as consumer protection and medicines laws, might achieve the 
desired objective. Speed of reaction may be more important 
than severity. Import bans can reduce pressure on local 
enforcement mechanisms.
3. Striking the right balance between swiftness of response to new 
substances, on the one hand, and suﬃ  cient scientiﬁ c evidence 
and legislative supervision, on the other, is an important 
policy goal.
6. The European Commission, in cooperation with EU countries, 
the EMCDDA and Europol, is working on new legislation to 
better address the control of new psychoactive substances 
throughout the EU. 
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